{
    "protocolSection": {
        "identificationModule": {
            "nctId": "NCT05016622",
            "orgStudyIdInfo": {
                "id": "2021-13204"
            },
            "organization": {
                "fullName": "Montefiore Medical Center",
                "class": "OTHER"
            },
            "briefTitle": "Booster Dose Trial",
            "officialTitle": "Safety and Efficacy of Booster Doses of BNT162b2 Vaccine in Immunocompromised Patients With a Cancer Diagnosis",
            "therapeuticArea": [
                "Oncology and Hematology"
            ],
            "study": "booster-dose-trial"
        },
        "statusModule": {
            "statusVerifiedDate": "2023-09",
            "overallStatus": "RECRUITING",
            "expandedAccessInfo": {
                "hasExpandedAccess": false
            },
            "startDateStruct": {
                "date": "2021-08-10",
                "type": "ACTUAL"
            },
            "primaryCompletionDateStruct": {
                "date": "2023-12",
                "type": "ESTIMATED"
            },
            "completionDateStruct": {
                "date": "2023-12",
                "type": "ESTIMATED"
            },
            "studyFirstSubmitDate": "2021-08-16",
            "studyFirstSubmitQcDate": "2021-08-16",
            "studyFirstPostDateStruct": {
                "date": "2021-08-23",
                "type": "ACTUAL"
            },
            "lastUpdateSubmitDate": "2023-09-18",
            "lastUpdatePostDateStruct": {
                "date": "2023-09-21",
                "type": "ACTUAL"
            }
        },
        "sponsorCollaboratorsModule": {
            "responsibleParty": {
                "type": "SPONSOR"
            },
            "leadSponsor": {
                "name": "Montefiore Medical Center",
                "class": "OTHER"
            },
            "collaborators": [
                {
                    "name": "Albert Einstein College of Medicine",
                    "class": "OTHER"
                }
            ]
        },
        "oversightModule": {
            "oversightHasDmc": true,
            "isFdaRegulatedDrug": true,
            "isFdaRegulatedDevice": false
        },
        "descriptionModule": {
            "briefSummary": "The goal of this study is to assess the safety and effectiveness of a COVID vaccine booster in patients with cancer who have not developed an antibody after the U.S. Food and Drug Administration (FDA) Emergency Use Authorized COVID vaccination series"
        },
        "conditionsModule": {
            "conditions": [
                "Cancer"
            ],
            "keywords": [
                "COVID-19",
                "Booster"
            ]
        },
        "designModule": {
            "studyType": "INTERVENTIONAL",
            "phases": [
                "PHASE2"
            ],
            "designInfo": {
                "allocation": "NA",
                "interventionModel": "SINGLE_GROUP",
                "primaryPurpose": "PREVENTION",
                "maskingInfo": {
                    "masking": "NONE"
                }
            },
            "enrollmentInfo": {
                "count": 250,
                "type": "ESTIMATED"
            }
        },
        "armsInterventionsModule": {
            "armGroups": [
                {
                    "label": "Booster dose",
                    "type": "EXPERIMENTAL",
                    "interventionNames": [
                        "Biological: BNT162b2 vaccine"
                    ]
                }
            ],
            "interventions": [
                {
                    "type": "BIOLOGICAL",
                    "name": "BNT162b2 vaccine",
                    "description": "administer an additional dose of the BNT162b2 mRNA vaccine to patients with cancer who have a negative SARS-CoV-2 Spike IgG at least 14 days after 2 doses of the mRNA vaccines (BNT162b2/mRNA-1273) or 28 days after the adenoviral based Ad26CoV2.S vaccine.",
                    "armGroupLabels": [
                        "Booster dose"
                    ]
                }
            ]
        },
        "outcomesModule": {
            "primaryOutcomes": [
                {
                    "measure": "Rates of seroconversion for SARS-CoV-2 spike antibody",
                    "timeFrame": "4 weeks after booster dose"
                }
            ]
        },
        "eligibilityModule": {
            "eligibilityCriteria": "Inclusion Criteria:\n\n* Above the age of 18\n* Known diagnosis of any malignancy- either active or completed therapy\n* Underwent an in-person encounter at a study facility during the study period\n* Have a negative SARS-CoV-2 spike IgG at least 14 days after the second dose of the mRNA-based vaccines (Moderna or Pfizer/BioNTech) or 28 days after a single dose of the adenovirus-based Johnson \\& Johnson vaccine.\n\nExclusion Criteria:\n\n* Patients who have had a serious adverse reaction to any prior COVID-19 vaccines resulting in emergency room visit or hospitalization, had events related to myocarditis, thrombosis and thrombocytopenia syndrome or anaphylaxis to any prior dose of the COVID-19 vaccines.\n* Patients who have had a documented COVID-19 infection in the 90 days prior to starting the study",
            "healthyVolunteers": false,
            "sex": "ALL",
            "minimumAge": "18 Years",
            "stdAges": [
                "ADULT",
                "OLDER_ADULT"
            ]
        },
        "contactsLocationsModule": {
            "centralContacts": [
                {
                    "name": "Balazs Halmos",
                    "role": "CONTACT",
                    "phone": "718-405-8404",
                    "email": "bahalmos@montefiore.org"
                }
            ],
            "locations": [
                {
                    "facility": "Montefiore Medical Center",
                    "status": "RECRUITING",
                    "city": "Bronx",
                    "state": "New York",
                    "zip": "10467",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 40.84985,
                        "lon": -73.86641
                    }
                }
            ]
        }
    },
    "derivedSection": {
        "miscInfoModule": {
            "versionHolder": "2024-07-30",
            "submissionTracking": {
                "estimatedResultsFirstSubmitDate": "2024-04-12",
                "submissionInfos": [
                    {
                        "releaseDate": "2024-04-12",
                        "resetDate": "2024-05-06",
                        "mcpReleaseN": 7
                    },
                    {
                        "releaseDate": "2024-07-05"
                    }
                ]
            }
        },
        "conditionBrowseModule": {
            "browseLeaves": [
                {
                    "id": "M2561",
                    "name": "COVID-19",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "BC01",
                    "name": "Infections"
                },
                {
                    "abbrev": "BC08",
                    "name": "Respiratory Tract (Lung and Bronchial) Diseases"
                },
                {
                    "abbrev": "All",
                    "name": "All Conditions"
                }
            ]
        },
        "interventionBrowseModule": {
            "browseLeaves": [
                {
                    "id": "M17360",
                    "name": "Vaccines",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "All",
                    "name": "All Drugs and Chemicals"
                }
            ]
        }
    },
    "hasResults": false
}